Insider Selling: Pulse Biosciences (NASDAQ:PLSE) Insider Sells $504,000.00 in Stock

by · The Cerbat Gem

Pulse Biosciences, Inc (NASDAQ:PLSE – Get Free Report) insider Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $25.20, for a total transaction of $504,000.00. Following the completion of the transaction, the insider owned 43,298 shares in the company, valued at approximately $1,091,109.60. The trade was a 31.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kevin Patrick Danahy also recently made the following trade(s):

  • On Monday, February 9th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The shares were sold at an average price of $21.45, for a total value of $429,000.00.

Pulse Biosciences Trading Down 1.7%

PLSE opened at $23.01 on Friday. Pulse Biosciences, Inc has a 12 month low of $12.56 and a 12 month high of $26.30. The business’s 50-day moving average price is $15.36 and its 200-day moving average price is $15.77. The company has a market cap of $1.56 billion, a P/E ratio of -20.36 and a beta of 1.77.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Mizuho set a $30.00 price target on shares of Pulse Biosciences in a report on Friday, February 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $26.00.

Get Our Latest Stock Analysis on Pulse Biosciences

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. AlphaQuest LLC lifted its holdings in Pulse Biosciences by 184.5% in the second quarter. AlphaQuest LLC now owns 8,864 shares of the company’s stock worth $134,000 after buying an additional 5,748 shares during the period. Inspire Investing LLC raised its position in shares of Pulse Biosciences by 19.7% in the 2nd quarter. Inspire Investing LLC now owns 25,891 shares of the company’s stock worth $391,000 after acquiring an additional 4,267 shares in the last quarter. Westside Investment Management Inc. lifted its stake in shares of Pulse Biosciences by 10.5% in the 2nd quarter. Westside Investment Management Inc. now owns 64,290 shares of the company’s stock valued at $970,000 after purchasing an additional 6,135 shares during the period. Quotient Wealth Partners LLC purchased a new position in shares of Pulse Biosciences in the 4th quarter valued at approximately $218,000. Finally, FourThought Financial Partners LLC bought a new stake in shares of Pulse Biosciences during the third quarter valued at approximately $355,000. 76.95% of the stock is owned by hedge funds and other institutional investors.

About Pulse Biosciences

(Get Free Report)

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.

Featured Articles